Less invasive staging for endometrial cancer put to the test
NCT ID NCT02598219
First seen Feb 01, 2026 · Last updated Jun 22, 2026 · Updated 21 times
Summary
This study compares a newer, less invasive sentinel node biopsy method to the standard way of staging early-stage endometrial cancers that have a medium or high risk of coming back. The goal is to see if the sentinel node approach causes fewer complications during and after surgery while still accurately detecting cancer spread. About 262 patients are taking part in this phase 3 trial across France.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON ENDOMETRIOID CARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Centre Georges François Leclerc
Dijon, France
-
Centre Hospitalier Régional Universitaire
Besançon, 25000, France
-
Centre Jean Perrin
Clermont-Ferrand, 63011, France
-
Centre Léon Bérard
Lyon, 69008, France
-
Centre Oscar Lambret
Lille, 59020, France
-
Centre Paul Strauss
Strasbourg, 67065, France
-
Hôpital Européen Georges Pompidou
Paris, 75015, France
-
Hôpital Jeanne de Flandres, CHRU Lille
Lille, 59037, France
-
Hôpital La Pitié-Salpêtrière
Paris, 75013, France
-
Hôpital Mère-Enfant, CHU Limoges
Limoges, 87042, France
-
ICM Val d'Aurelle
Montpellier, 34298, France
-
Institut Bergonié
Bordeaux, 33076, France
-
Institut Claudius Regaud
Toulouse, 31059, France
-
Institut Paoli Calmettes
Marseille, 13273, France
-
Institut de Cancérologie de l'Ouest, René Gauducheau
Saint-Herblain, 44805, France
-
Polyclinique Urbain V
Avignon, 84036, France
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Pre-operative sentinel node mapping with radionucleide (Nanocis, Nanocoll, or Rotop-nanoHSA)
What this could lead to
If successful, this could show that sentinel node biopsy is safer and just as effective as standard staging for certain endometrial cancers, potentially becoming the new standard of care.
What could go wrong
This is a phase 3 trial, but it only compares two staging methods—it does not test a new treatment. The results may not apply to all patients, and sentinel node mapping might miss some cancer spread.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.